Dimerix (DXB) Q2 2026 TU earnings summary

Executive summary

• Completed target recruitment of 286 adult patients for the ACTION3 Phase 3 trial in FSGS kidney disease, with pediatric recruitment ongoing as an independent cohort.

• Announced successful data analysis from the PARASOL collaboration, supporting the use of proteinuria endpoints for regulatory approval.

• Received FDA input confirming proteinuria reduction as a suitable primary endpoint for traditional approval, with eGFR as a secondary endpoint.

• 7th successful Independent Data Monitoring Committee review of ACTION3 completed.

• BioMarin announced intention to acquire US partner Amicus Therapeutics.

• CEO awarded 'CEO of the Year' by Biotech Daily.

Financial highlights

• Cash position at 31 December 2025 was AU$38.5 million, down from AU$49.2 million at 30 September 2025.

• Net operating cash outflows for the December quarter were AU$11.1 million, primarily related to clinical trial and R&D expenses.

• Estimated 3.5 quarters of funding available based on current cash burn.

• Aggregate payments to related parties for the quarter totaled AU$183,000.

Outlook and guidance

• Well positioned to fund ongoing operations and the ACTION3 Phase 3 trial, with continued focus on licensing opportunities in unlicensed territories.

• Update on next steps for the ACTION3 trial expected in early 2026 following further FDA feedback.